15 results about "Apoptosis signaling" patented technology

The present application provides an indole derivative and a preparation method and application thereof. The preparation method comprises the following steps: dissolving copper acetate and triethylamine in isopropyl alcohol, stirring until completely dissolved to obtain a reaction medium; adding 5-bromo indigo and indole into the reaction medium, fully stirring at room temperature until the reaction is completely converted; removing the reaction solvent by distillation to obtain a crude product, purifying and recrystallizing to obtain a high-purity solid powder of the indole derivative. The indole derivative has a significant inhibitory effect on tyrosinase, melanin production and transfer; has high antioxidant capacity for scavenging intracellular active oxygen free radicals; through the mechanisms of affecting the membrane potential of mitochondria, activating the related apoptosis signaling pathway and promoting the expression of apoptosis proteins, etc., the A549 cell is prompted to enter the apoptosis program, thereby providing a new potential strategy and research direction for the apoptosis regulation of tumor cells, and having important research value and application prospect.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

The invention discloses a method for indicating fish freshness change by adopting cell apoptosis signal molecules and application, and belongs to the technical field of grass carp freshness detection. The invention discloses a method for indicating fish freshness change by adopting cell apoptosis signal molecules, which comprises the following steps: according to the detected contents of cell apoptosis signal molecules Caspase-3, Bax, Bcl-2 and Cyt-c, establishing a corresponding relation model between the content of the cell apoptosis signal molecules and the freshness of grass carp. According to the method, the freshness of the grass carp can be quickly and accurately judged, and a scientific basis is provided for quality control and market supervision of the grass carp. The method can be popularized and applied in actual production and market supervision.

This invention discloses the application of substances that inhibit Trx1 nitration in the preparation of drugs for treating Trx1 nitration-related diseases. This invention reveals for the first time that nitration modification of tyrosine residue 49 (Y49) of the Trx1 protein is a key pathological step in diseases such as ischemic stroke and myocardial ischemia-reperfusion injury. Inhibiting nitration at this site can effectively restore Trx1 reductase activity, enhance the binding of Trx1 to ASK1, and block the downstream ASK1-p38 / JNK apoptosis signaling pathway, thereby exerting a therapeutic effect. This invention provides a novel treatment strategy for Trx1 nitration-related diseases.

The invention relates to lactobacillus paracasei for inhibiting cytotoxicity of methylglyoxal, and belongs to the technical field of biology. The invention provides a lactobacillus paracasei L5 which can be used for remarkably inhibiting cytotoxicity induced by methylglyoxal (MGO) and improving the cell survival rate. The lactobacillus paracasei can improve MGO-induced cytotoxicity by improving the activity of antioxidant enzymes such as SOD, GXP-PX and CAT, enhancing the function of a glyoxalase detoxification system, reducing inflammatory response and oxidative stress level, inhibiting Caco-2 cell apoptosis, up-regulating expression of key genes in MAPK, AGE-RAGE and cell apoptosis signal channels and enriching lipid metabolism and energy metabolism pathways.

The present invention relates to the use of Apoptosis Signal-Regulating Kinase-1 (ASK-1) inhibitor compounds for the treatment of organ diseases and disorders, wherein the organ disease or disorder is selected from a liver, heart disease, kidney, pancreas, spleen, or skin disease or disorder.

The present disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent such as a CNTF compound, a C-type natriuretic peptide (CNP) compound, a Tie-2 agonist, a natriuretic peptide receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or a FAS-ligand (FASL) inhibitor, any combination comprising these compounds, and a sustained release component. Methods, medicaments, kits, uses and methods of manufacture for treating glaucoma or related conditions are also described.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

To provide a drug delivery system for treating glaucoma or related conditions.SOLUTION: Provided is a drug delivery system comprising (1) a prostaglandin, a CNTF compound, a TNF-α / TNFR inhibitor, a FAS or FASL inhibitor, or any combination thereof, and (2) a sustained delivery component.SELECTED DRAWING: None

To provide a drug delivery system comprising a sustained delivery component.SOLUTION: This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, a cysteine-aspartic protease inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.SELECTED DRAWING: None

This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease (caspase) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.

The invention relates to the field of medicines, and discloses an application of tetrahydropalmatine in preparation of a chemotherapy sensitizing medicine and the chemotherapy sensitizing medicine. The tetrahydropalmatine disclosed by the invention is applied to the chemotherapy sensitizing medicine, and can inhibit cell activity, inhibit cell proliferation, promote cell apoptosis and inhibit cell migration. The chemotherapy sensitizing drug is used for increasing the sensitivity of malignant tumors to chemotherapy drugs, and after tetrahydropalmatine and paclitaxel are combined for use, the survival rate of paclitaxel to ovarian cancer drug-resistant cells A2780 / Taxol is only 30.38%. Tetrahydropalmatine and paclitaxel are combined to weaken the anti-apoptosis ability and enhance the apoptosis promoting ability by regulating the Bcl-2 / Bax ratio, and conduction of an apoptosis signal channel is promoted by activating a Caspase cascade reaction. The combined use of the tetrahydropalmatine and the paclitaxel can almost completely inhibit the migration of A2780 / Taxol cells within 48 hours.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

The application discloses application of 1-aminocyclopropane carboxylic acid in preparation of a glioma treatment drug. The 1-aminocyclopropane carboxylic acid of the application not only significantly inhibits the expression level of glial fibrillary acidic protein of glioma cells, but also effectively inhibits the expression and phosphorylation modification of extracellular signal-regulated kinase 1 / 2 and protein kinase B, blocks the cell proliferation signal mediated by the MAPK / ERK and PI3K / Akt / mTOR signal pathways, and activates the cell apoptosis signal mediated by caspase 3, so that the proliferation of glioma cells is inhibited, the growth speed of a xenograft of a nude mouse is effectively slowed down, the volume and mass of tumor tissues are significantly reduced, and a significant therapeutic effect is achieved.

To provide a drug delivery system to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction.SOLUTION: A drug delivery system comprises a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is a peptide derivative of ciliary neurotrophic factor (CNTF) comprising the peptide sequence DGGL, and the first API is a peptide represented by SEQ ID NO: 2 (peptide 21: Ac-DGGLAG-NH2). The drug delivery system is used for injection into mammal eyes.SELECTED DRAWING: None